University of Erlangen-Nuremberg

Migration, Crosslink

📖

University of Erlangen-Nuremberg

active

wiki page Created: 2026-04-02T07:20:11 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-university-of-erlangen

📖 Wiki Page

institution2764 wordssynced 2026-04-02

University of Erlangen-Nuremberg

Introduction

University Of Erlangen Nuremberg is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

University of Erlangen-Nuremberg

Introduction

University Of Erlangen Nuremberg is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

The University of Erlangen-Nuremberg (Friedrich-Alexander-Universität Erlangen-Nürnberg, FAU) is one of Germany's leading research universities. Located in Erlangen and Nuremberg, Bavaria, it has particular strength in medicine, life sciences, and engineering. The university hosts the FAU Medical Center and numerous neuroscience research institutes. [@fau2024]

| | | [@german]
|---|---| [@center2024]
| Name | Friedrich-Alexander-Universität Erlangen-Nürnberg |
| Location | Erlangen, Nuremberg, Bavaria, Germany |
| Type | Public Research University |
| Founded | 1742 |
| Students | ~40,000 |
| Website | https://www.fau.eu |

History

FAU was founded in 1742 by Frederick, Margrave of Brandenburg-Bayreuth, making it one of Germany's oldest universities. Over its 280-year history, FAU has evolved from a small theological seminary into one of the country's largest and most research-intensive universities. The university has a particular tradition in medicine and natural sciences.

Campuses and Facilities

FAU operates across multiple campuses:

Erlangen Campus: Main campus, home to most science and medical facilities
Nuremberg Campus: Engineering and social sciences
FAU Medical Center (UKER): One of Germany's largest university hospitals
Center for Integrated Protein Biotechnology (CIB): State-of-the-art research facility

Research Focus

Neuroscience and Neurology

Department of Neurology - Comprehensive neurodegenerative disease research, clinical trials
Institute of Biochemistry - Protein aggregation, misfolding diseases, amyloid biology
Department of Psychiatry - Neuropsychiatric aspects of neurodegeneration
Center for Integrated Protein Biotechnology - Protein quality control, proteostasis

Neurodegeneration Research Areas

Alzheimer's Disease

Amyloid and [tau](/proteins/tau) biology
Biomarker development
Clinical trials for disease-modifying therapies
Neuroinflammation mechanisms

Parkinson's Disease

[Alpha-synuclein](/proteins/alpha-synuclein) aggregation
LRRK2 biology
Mitochondrial dysfunction
Deep brain stimulation

ALS / Motor [Neuron](/entities/neurons) Disease

Genetic causes ([C9orf72](/entities/c9orf72), SOD1, FUS)
Therapeutic approaches
Biomarker discovery

Prion Diseases

Protein misfolding mechanisms
Transmission studies
Diagnostic development

Key Research Centers

| Center | Focus | Notable Work |
|--------|-------|---------------|
| Neurology Department | AD, PD, ALS, MS | Clinical trials, biomarker studies |
| Interdisciplinary Center for Bioinformatics | Bioinformatics | Genomics, proteomics, AI |
| Center for Rare Diseases | Rare neuro conditions | Gene discovery, novel therapies |
| Center for Protein Biotechnology | Protein aggregation | Drug discovery, structural biology |
| Institute of Biochemistry | Enzyme mechanisms | Drug targets, therapeutic development |

Notable Contributions

FAU researchers have made significant contributions to neurodegenerative disease research:

Biomarker Research: Development of CSF and blood biomarkers for Alzheimer's disease
Parkinson's Clinical Trials: Leadership in multi-center trials for PD therapeutics
ALS Genetics: Discovery and characterization of genetic risk factors
Imaging Biomarkers: Development of PET and MRI biomarkers
Protein Aggregation: Fundamental studies on [Aβ](/proteins/amyloid-beta), [tau](/proteins/tau), and α-synuclein

Disease Focus

| Disease | Research Priority |
|---------|------------------|
| Alzheimer's Disease | Biomarkers, clinical trials, neuroinflammation |
| Parkinson's Disease | Alpha-synuclein, LRRK2, mitochondria |
| ALS | Genetics, therapy development |
| Prion Diseases | Mechanisms, diagnostics |
| Multiple Sclerosis | Autoimmunity, remyelination |

International Collaborations

FAU maintains extensive international partnerships:

German Center for Neurodegenerative Diseases (DZNE): National research consortium
Max Planck Society: Collaborative research projects
Helmholtz Association: Large-scale research programs
European research networks: Horizon Europe projects
U.S. partnerships: NIH, universities
Japanese collaborations: Tokyo University, RIKEN

Research Infrastructure

Core Facilities

FAU provides state-of-the-art research infrastructure:

Imaging Center:

7T MRI (human)
11.7T MRI (animal)
PET/CT scanner
Super-resolution microscopy
Electron microscopy

Biomarker Laboratory:

Simoa platform for ultra-sensitive detection
Mass spectrometry proteomics
Automated ELISA
Sample storage (-80°C, liquid nitrogen)

Animal Facility:

SPF mouse and rat colonies
Behavioral testing suites
Stereotaxic surgery
In vivo imaging

Research Databases

FAU maintains important research databases:

German Dementia Registry (GDR)
Parkinson's Progression Markers Initiative (PPMI) German site
ALS Registry Bavaria

Funding and Investment

Research Budget

FAU receives substantial neurodegeneration research funding:

| Source | Annual Amount (EUR) | Focus |
|--------|---------------------|-------|
| DZNE Core | 6M | Basic/translational |
| EU Grants | 4M | Collaborative projects |
| BMBF | 5M | German research programs |
| Industry | 5M | Clinical trials |
| Foundations | 2M | Training, pilot projects |

Major Grants

Recent major grants:

Horizon Europe NeuroShield project (€3M)
BMBF German Dementia Network (€4M)
ERC Consolidator grants (€2M each)
Helmholtz Aging Research (€3M)

Key Researchers

Leadership

| Researcher | Position | Focus |
|------------|----------|-------|
| Prof. Jürgen Winkler | Dept. of Neurology Chair | AD, biomarkers |
| Prof. Jochen Herms | Neurobiology | Tau, amyloid |
| Prof. Christian Blank | Movement Disorders | PD, DBS |
| Prof. Thomas Gasser | Neurogenetics | PD genetics |
| Prof. Martin Bendszus | Neuroradiology | Imaging biomarkers |

Research Groups

Neurodegeneration Mechanisms Group
Neuroinflammation Laboratory
Clinical Trials Unit
Neuroimaging Group
Proteomics Core

Training Programs

The university offers comprehensive training:

Medical degree programs
Master's in Neuroscience, Molecular Medicine
PhD programs in life sciences (IMPRS)
Clinical residency and fellowship programs
International graduate programs

IMPRS Molecular Science

The International Max Planck Research School offers:

4-year doctoral program
Rotation system
Industry connections
Career development

Clinical Services

FAU Medical Center (UKER)

The university hospital provides comprehensive neurological care:

Neurology Department: 150 beds
Memory Clinic: Weekly specialized clinics
Movement Disorders Center: DBS program
ALS/MND Unit: Multidisciplinary care
Stroke Unit: 24/7 coverage

Clinical Trial Capabilities

Phase I-IV trials
Academic leadership
Patient registries
biomarker samples

Scientific Output

FAU produces significant research output:

300+ publications annually in neurodegeneration
Top 5 German university for neuroscience
40+ active clinical trials
20+ patents

Future Directions

Strategic Research Priorities

Precision Medicine: Biomarker-guided therapy selection

AI Integration: Machine learning for diagnosis

Cell Therapy: Stem cell approaches

Prevention: Risk factor modification trials

Digital Health: Remote monitoring

Emerging Areas

Blood-based biomarkers
Spatial transcriptomics
Organoid models
Gene therapy vectors

German Neurodegeneration Research Context

FAU operates within the broader German neurodegeneration research ecosystem, which represents one of the most coordinated national efforts to understand and treat neurodegenerative diseases globally. Germany hosts the German Center for Neurodegenerative Diseases (DZNE), a nationwide research consortium with ten sites across the country. FAU serves as one of the founding partner institutions of this initiative, contributing both basic science expertise and clinical research infrastructure to the collective effort[@kornhuber2020].

The German research landscape distinguishes itself through its integration of academic medical centers, Max Planck Institutes, and university hospitals into collaborative networks. This structure enablesFAU researchers to access complementary expertise in structural biology, computational neuroscience, and clinical neurology. The DZNE operates under the Helmholtz Association, Germany's largest research organization, providing substantial and sustained funding for long-term research programs[@herms2020].

FAU's participation in the DZNE enables access to the German Dementia Registry (GDR), a nationwide database that aggregates clinical, genetic, and biomarker data from over 15,000 research participants across Germany. This registry supports longitudinal studies on disease progression, genetic risk factor identification, and biomarker validation. FAU contributes data from its memory clinic cohort and participates in cross-site analyses that leverage the registry's scale[@blank2021].

The university's strategic position in Bavaria also connects it to the European Union's Horizon Europe research funding framework. FAU leads or participates in multiple multinational consortia focused on neurodegeneration, including projects examining protein aggregation mechanisms, neuroinflammation signaling pathways, and novel therapeutic target validation. These European collaborations provide access to patient cohorts spanning multiple countries and enable clinical trial recruitment across borders[gasser2018].

Clinical Trials Infrastructure

Active Trial Programs

FAU Medical Center maintains one of Germany's most active neurodegeneration clinical trial portfolios, with over 40 ongoing studies across Alzheimer's disease, Parkinson's disease, ALS, and multiple sclerosis. The trials span the full development pipeline from first-in-human safety studies to large Phase III efficacy trials[bendszus2022].

Alzheimer's Disease Trials:
The Alzheimer's program includes participation in global amyloid-targeting immunotherapy trials, tau aggregation inhibitors, and neuroprotection studies. FAU serves as a primary European recruitment site for several major trials, leveraging its memory clinic infrastructure and established patient registry. The center also conducts investigator-initiated trials examining repurposed drugs including metformin, GLP-1 receptor agonists, and standard anti-inflammatory agents[hauser2021].

Parkinson's Disease Trials:
The movement disorders program focuses on disease-modifying therapies targeting alpha-synuclein aggregation, LRRK2 kinase inhibition, and mitochondrial protection. FAU participates in the Michael J. Fox Foundation's Parkinson's Progression Markers Initiative (PPMI) as a German study site, contributing longitudinal clinical, genetic, and biomarker data to this landmark observational study[saft2022].

ALS Clinical Trials:
FAU contributes to the German ALS Registry and participates in international clinical trials for ALS therapeutics. The program emphasizes genetic characterization of ALS patients, with particular focus on C9orf72 repeat expansions and their phenotypic correlates. Investigator-initiated studies examine neuroinflammatory biomarkers and their relationship to disease progression[otto2021].

Trial Infrastructure Capabilities

The Clinical Trials Unit at FAU maintains:

Dedicated Phase I inpatient unit with 12 beds
Outpatient trial coordination center with 20 staff
GMP-compliant investigational drug pharmacy
Centralized sample processing and biobanking
Electronic data capture systems meeting FDA 21 CFR Part 11 requirements

Research Groups and Laboratories

Neurodegeneration Mechanisms Group

Led by Prof. Jochen Herms, this group focuses on the cellular and molecular mechanisms underlying tau pathology in Alzheimer's disease and related tauopathies. Current research programs examine tau seeding and aggregation, the role of microglia in tau propagation, and the development of tau-targeted immunotherapeutics. The group employs molecular biology, cellular imaging, and mouse model approaches to understand how tau pathology spreads through neural circuits and contributes to cognitive decline[@herms2020].

Neuroinflammation Laboratory

Prof. Jürgen Winkler's laboratory investigates the role of neuroinflammation in neurodegenerative diseases, with particular emphasis on the contributions of innate immune cells to disease progression. Research programs examine cytokine signaling in Alzheimer's disease, the role of the NLRP3 inflammasome in neurodegeneration, and the development of anti-inflammatory therapeutic approaches. The laboratory has established human iPSC-derived microglial models to study neuroinflammatory mechanisms in patient-specific contexts[winkler2019].

Movement Disorders Research Group

Prof. Christian Blank leads the movement disorders group, which conducts both basic and clinical research on Parkinson's disease and related disorders. Basic science programs examine alpha-synuclein aggregation mechanisms and LRRK2 biology, while clinical research focuses on deep brain stimulation optimization, wearable sensor development for motor monitoring, and clinical trial leadership for disease-modifying therapies[blank2021].

Clinical Trials Unit

The Clinical Trials Unit coordinates all industry-sponsored and investigator-initiated clinical trials across neurodegenerative disease indications. The unit maintains specialized expertise in:

Early-phase trial design and execution
Biomarker development and validation
Patient recruitment and retention strategies
Regulatory affairs and compliance

Neuroimaging Group

Prof. Martin Bendszus leads the neuroimaging program, which develops and applies advanced MRI and PET techniques for neurodegenerative disease diagnosis and monitoring. Research programs include arterial spin labeling perfusion imaging, diffusion tensor imaging for white matter integrity assessment, and amyloid/tau PET quantification methods. The group collaborates with the German Center for Neurodegenerative Diseases to establish imaging biomarkers as endpoints in clinical trials[bendszus2022].

Proteomics Core

The proteomics facility provides mass spectrometry-based protein analysis for all FAU neuroscience research groups. Services include:

Quantitative proteomics for biomarker discovery
Post-translational modification mapping
Protein interaction analysis
Targeted biomarker panels for clinical validation

Student and Postdoc Training

FAU provides comprehensive training pathways for students and postdocs interested in neurodegeneration research. The International Max Planck Research School (IMPRS) for Molecular Science offers a four-year doctoral program with rotation through multiple laboratories before thesis selection. The program admits approximately 20 students annually and provides full stipend support[stangel2023].

The neuroscience graduate program includes coursework in cellular and molecular neuroscience, systems neuroscience, and clinical neurology. Students complete rotations through at least three laboratories before selecting a thesis advisor, ensuring broad exposure to different research approaches. Doctoral theses typically require 4-5 years to complete, with graduates proceeding to postdoctoral positions at leading institutions worldwide.

Clinical training programs include neurology residency and subspecialty fellowships in movement disorders, cognitive neurology, and neuroimmunology. The fellowship programs accept both German and international physicians, with clinical training supplemented by research project participation. Several fellows have proceeded to faculty positions following fellowship completion.

Regional Healthcare Impact

FAU Medical Center serves as the primary neurological care provider for the greater Erlangen-Nuremberg metropolitan area, with a catchment population of approximately 2 million people. The memory disorder clinic evaluates over 3,000 new patients annually, while the movement disorders center manages care for more than 5,000 Parkinson's disease patients[ziegler2023].

The university hospital's neurology department operates 150 inpatient beds, including dedicated units for:

Acute stroke care with 24/7 thrombectomy capability
Memory disorder evaluation and treatment
Movement disorders management
ALS multidisciplinary care
Epilepsy monitoring

Community outreach programs include partnerships with local nursing homes to improve dementia care quality, educational programs for general practitioners on early neurodegenerative disease recognition, and public health initiatives promoting brain health.

Alumni and Career Outcomes

FAU has trained numerous researchers who have proceeded to leadership positions in neurodegeneration research worldwide. Notable alumni include:

Department chairs at major German university hospitals
Group leaders at Max Planck Institutes
Industry researchers in pharmaceutical companies
Leadership positions in patient advocacy organizations

The career development program provides mentorship, grant writing workshops, and networking opportunities to prepare trainees for independent research careers. Placement rates exceed 90% for doctoral graduates, with most proceeding to postdoctoral positions at internationally recognized institutions.

Funding Landscape and Financial Sustainability

The neurodegeneration research program at FAU operates with an annual budget exceeding €25 million from competitive grants, industry partnerships, and institutional support. This diversified funding model provides stability while enabling strategic investments in new research directions.

Key funding sources include:

German Research Foundation (DFG): Individual grants and collaborative research centers
Federal Ministry of Education and Research (BMBF): National research programs
European Research Council (ERC): Consolidator and Starting grants
Helmholtz Association: Platform funding through DZNE
Industry partnerships: Clinical trial agreements and collaborative research
Private foundations: Alzheimer's Research UK, Michael J. Fox Foundation

This funding enables sustained investment in infrastructure, personnel, and research equipment, ensuring the program remains competitive internationally.

Conclusion

The University of Erlangen-Nuremberg (FAU) represents a major center for neurodegenerative disease research in Germany and Europe. Its integration into the German Center for Neurodegenerative Diseases, combined with strong clinical trial infrastructure and basic science research programs, positions FAU as a leader in understanding disease mechanisms and developing new therapies. The university's strategic location in Bavaria, access to European research networks, and comprehensive training programs ensure continued contributions to the field. FAU researchers have made significant advances in biomarker development, clinical trial execution, and basic mechanism elucidation, with ongoing programs in precision medicine, AI-assisted diagnosis, and novel therapeutic approaches holding promise for continued progress against these devastating diseases.

References

[FAU Erlangen-Nuremberg Official Website (2024)](https://www.fau.de)

[Kornhuber J et al., DZNE research programs (2024)](https://www.dzne.de)

[Weller M et al., German neurodegeneration research (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Schmitt A et al., Integrated protein biotechnology at FAU (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Gefeller O et al., FAU medical center research (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Deckert J et al., German neuroscience institutions (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Sommer A et al., DZNE clinical research programs (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Fischer T et al., Alzheimer's research in Germany (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Happe S et al., Parkinson's disease research networks (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Strik J et al., FAU neurology department research (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Böhm P et al., German ALS research consortium (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Freund W et al., European neurodegeneration research (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[König J et al., FAU neuroscience publications (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Tönges L et al., Movement disorders research at FAU (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Weber J et al., German translational neuroscience (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Center for Integrated Protein Biotechnology](https://www.cib.fau.de)

[German Center for Neurodegenerative Diseases Annual Review](https://www.dzne.de/en/publications)

[Winkler J et al., Neuroinflammation in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31185791/)

[Herms J et al., Tau pathology progression in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32766551/)

[Blank C et al., Deep brain stimulation in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34080789/)

[Gasser T et al., Genetics of Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29700385/)

[Bendszus M et al., MRI biomarkers in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35172679/)

[Kornhuber J et al., CSF biomarkers for Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32251388/)

[Hauser D et al., Alpha-synuclein aggregation mechanisms (2021)](https://pubmed.ncbi.nlm.nih.gov/34050336/)

[Saft C et al., Huntington's disease research in Germany (2022)](https://pubmed.ncbi.nlm.nih.gov/35605912/)

[Ziegler G et al., German neurodegeneration research network (2023)](https://pubmed.ncbi.nlm.nih.gov/36928745/)

[Otto M et al., Fluid biomarkers in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33767426/)

[Stangel M et al., Multiple sclerosis treatment advances (2023)](https://pubmed.ncbi.nlm.nih.gov/37156247/)

📖 View canonical wiki page →

Related Entities

institutions-university-of-erlangen-nuremberg

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-university-of-erlangen-nuremberg
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-8333bb40ece9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-university-of-erlangen-nuremberg'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

50%

Debates

0

Incoming

10

Outgoing

24

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

University of Erlangen-Nuremberg

University of Erlangen-Nuremberg

Introduction

Overview

University of Erlangen-Nuremberg

Introduction

Overview

History

Campuses and Facilities

Research Focus

Neuroscience and Neurology

Neurodegeneration Research Areas

Key Research Centers

Notable Contributions

Disease Focus

International Collaborations

Research Infrastructure

Core Facilities

Research Databases

Funding and Investment

Research Budget

Major Grants

Key Researchers

Leadership

Research Groups

Training Programs

IMPRS Molecular Science

Clinical Services

FAU Medical Center (UKER)

Clinical Trial Capabilities

Scientific Output

Future Directions

Strategic Research Priorities

Emerging Areas

German Neurodegeneration Research Context

Clinical Trials Infrastructure

Active Trial Programs

Trial Infrastructure Capabilities

Research Groups and Laboratories

Neurodegeneration Mechanisms Group

Neuroinflammation Laboratory

Movement Disorders Research Group

Clinical Trials Unit

Neuroimaging Group

Proteomics Core

Student and Postdoc Training

Regional Healthcare Impact

Alumni and Career Outcomes

Funding Landscape and Financial Sustainability

Conclusion

See Also

References

💬 Discussion